Pharmaceutical News

RSS

Nimodipine reduces febrile seizures

Fever-induced childhood seizures, known as febrile seizures, can be terrifying for parents to witness. The full-body convulsions, which mostly affect children six months to five years old, can last from mere seconds up to more than 40 minutes. Currently, children are not treated with daily anticonvulsant medication to prevent these seizures even when they recur repeatedly because toxic side effects of existing treatments outweigh potential benefits.

12 Jun 2013

CLAAD urges FDA to implement Obama administration's policy on safer opioid medications

The Center for Lawful Access and Abuse Deterrence joined in signing a Citizen Petition filed today urging the Food and Drug Administration to fully implement the Obama administration's policy supporting a market transition to safer opioid medications.

11 Jun 2013

Oceans Omega produces omega-3 fortified gelatins in partnership with Lakeview Farms

Oceans Omega, a leading supplier of water-soluble omega-3 EPA and DHA ingredients for food, beverage, nutritional and pet care products, announced today the world's first commercially produced omega-3 fortified gelatins.

11 Jun 2013

Questcor acquires rights to develop Synacthen and Synacthen Depot in US

Questcor Pharmaceuticals, Inc. today announced it has acquired rights to develop Synacthen and Synacthen Depot in the U.S. from Novartis Pharma AG and Novartis AG.

11 Jun 2013

Rapamycin improves cardiac function in mice suffering from age-related heart disease

Elderly mice suffering from age-related heart disease saw a significant improvement in cardiac function after being treated with the FDA-approved drug rapamycin for just three months.

11 Jun 2013

First Edition: June 11, 2013

Today's headlines include coverage of the Obama administration's decision to drop the fight to keep age restrictions in place for Plan B emergency contraceptive pill sales.

11 Jun 2013

Vertical Pharmaceuticals, Nautilus Neurosciences sign co-promotion agreement for Lorzone

Vertical Pharmaceuticals, Inc. today announced that Vertical and Nautilus Neurosciences have entered into a co-promotion agreement for Lorzone (chlorzoxazone tablets, USP), a safe, effective, and fast-acting muscle relaxant that is not associated with significant sedation or drowsiness.

11 Jun 2013

Findings link antihistamine use to adverse pregnancy outcomes

Women with a severe form of morning sickness who take antihistamines to help them sleep through their debilitating nausea are significantly more likely to experience adverse pregnancy outcomes, including low birth weight babies and premature births, a UCLA study has found.

11 Jun 2013

Novel approach to pain therapy paves way for lower dosage painkillers

For patients managing cancer and other chronic health issues, painkillers such as morphine and Vicodin are often essential for pain relief. The body's natural tendency to develop tolerance to these medications, however, often requires patients to take higher doses - increasing risks of harmful side effects and dependency.

11 Jun 2013

European Commission grants orphan drug designation for maribavir for treatment of CMV disease

ViroPharma Incorporated today announced that the European Commission has granted orphan drug designation for maribavir for treatment of cytomegaloviral disease in patients with impaired cell mediated immunity.

11 Jun 2013

Chronic myeloid leukemia patients treated with tyrosine kinase inhibitors have quality-of-life issues

Researchers at Moffitt Cancer Center have determined that chronic myeloid leukemia patients who are treated with a class of oral chemotherapy drugs known as a tyrosine kinase inhibitors have significant side effects and quality-of-life issues that need to be addressed. Some of these issues include depression, fatigue, nausea and change of appearance.

11 Jun 2013

African medicinal plants contain chemicals that may help stop spread of cancer cells

African medicinal plants contain chemicals that may be able to stop the spread of cancer cells. This is the conclusion of researchers following laboratory experiments conducted at Johannes Gutenberg University Mainz (JGU).

10 Jun 2013

Mandatory influenza vaccination does not lead to excessive voluntary termination

Mandatory influenza (flu) vaccination, as a condition of employment, did not lead to excessive voluntary termination, according to a four-year analysis of vaccination rates at Loyola University Medical Center in Maywood, IL.

10 Jun 2013

BioLineRx signs out-licensing agreement with CTTQ to develop, commercialize Hepatitis C drug

BioLineRx, a biopharmaceutical development company, announced today that it has signed an out-licensing agreement with Jiangsu Chia-tai Tianqing Pharmaceutical Co., Ltd., the leading Chinese pharmaceutical company in the liver disease therapeutic area, for the development and commercialization of BL-8030, an orally available treatment for the Hepatitis C virus.

10 Jun 2013

Drug used to control Type II diabetes can help repair spinal cords of mice suffering from inherited disease

A drug used to control Type II diabetes can help repair the spinal cords of mice suffering from the inherited disease adrenoleukodystrophy which, untreated, leads eventually to a paralysis, a vegetative state and death.

10 Jun 2013

NanoViricides files Orphan Drug application with FDA for DengueCide

NanoViricides, Inc. announced today that it has filed an Orphan Drug application with the Office of Orphan Product Development of the US FDA for DengueCide, its drug candidate for the treatment of dengue and dengue hemorrhagic fever.

10 Jun 2013

Common antidepressant medications may impair a form of learning, new report suggests

An interesting new report of animal research published in Biological Psychiatry suggests that common antidepressant medications may impair a form of learning that is important clinically.

10 Jun 2013

AVEO Oncology receives Complete Response letter from FDA for tivozanib NDA

AVEO Oncology today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration informing the company that the FDA will not approve in its present form the New Drug Application for AVEO's investigational agent tivozanib for the treatment of patients with advanced renal cell carcinoma.

10 Jun 2013

Edge Therapeutics announces FDA acceptance of IND application for EG-1962

Edge Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing life-saving hospital products for acute, fatal or debilitating conditions, announced today that the U.S. Food and Drug Administration has accepted the Company's Investigational New Drug application for EG-1962, a novel bio-absorbable nimodipine microparticle formulation.

10 Jun 2013

Faldaprevir+ achieves viral cure in 88% of treatment-naïve genotype-1 hepatitis C patients in Asia

New findings presented today during the APASL Liver Week in Singapore, highlighted the efficacy and safety of faldaprevir+ plus pegylated interferon and ribavirin (PegIFN/RBV) in treatment-naïve patients with genotype-1 hepatitis C virus (HCV) in Asia.1 This post-hoc sub-analysis of the Phase III STARTVerso™1 and 2 trials showed that both doses of faldaprevir were associated with high viral cure rates and a shorter treatment duration in this particular patient group.1

10 Jun 2013

Pharmaceutical News

Nimodipine reduces febrile seizures

CLAAD urges FDA to implement Obama administration's policy on safer opioid medications

Oceans Omega produces omega-3 fortified gelatins in partnership with Lakeview Farms

Questcor acquires rights to develop Synacthen and Synacthen Depot in US

Rapamycin improves cardiac function in mice suffering from age-related heart disease

First Edition: June 11, 2013

Vertical Pharmaceuticals, Nautilus Neurosciences sign co-promotion agreement for Lorzone

Findings link antihistamine use to adverse pregnancy outcomes

Novel approach to pain therapy paves way for lower dosage painkillers

European Commission grants orphan drug designation for maribavir for treatment of CMV disease

Chronic myeloid leukemia patients treated with tyrosine kinase inhibitors have quality-of-life issues

African medicinal plants contain chemicals that may help stop spread of cancer cells

Mandatory influenza vaccination does not lead to excessive voluntary termination

BioLineRx signs out-licensing agreement with CTTQ to develop, commercialize Hepatitis C drug

Drug used to control Type II diabetes can help repair spinal cords of mice suffering from inherited disease

NanoViricides files Orphan Drug application with FDA for DengueCide

Common antidepressant medications may impair a form of learning, new report suggests

AVEO Oncology receives Complete Response letter from FDA for tivozanib NDA

Edge Therapeutics announces FDA acceptance of IND application for EG-1962

Faldaprevir+ achieves viral cure in 88% of treatment-naïve genotype-1 hepatitis C patients in Asia

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News